Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Melanie Griffin

Newcastle AuthorsTitleYearFull text
Melanie Griffin
Dr Claire Jennings
Professor Gareth Veal
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemia2021
Dr Britta Vormoor
Professor Gareth Veal
Melanie Griffin
Professor Julie Irving
Lynne Minto
et al.		A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia2017
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al.		Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.		A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Professor Andrew Pearson
Dr Quentin Campbell Hewson
Professor Alan Boddy
Melanie Griffin
A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study2015
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al.		Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil2014
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.		Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Melanie Griffin
Professor Alan Boddy
Professor Andrew Pearson
Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia2010
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.		Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Professor Ruth Plummer
Melanie Griffin
Dr Sally Coulthard
Julieann Sludden
Professor Hilary Calvert
et al.		Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors2009
Professor Ruth Plummer
Professor Alan Boddy
Melanie Griffin
Dr Mark Verrill
A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies2008
Professor Alan Boddy
Melanie Griffin
Julie Errington
Professor Gareth Veal
Dosing of cancer patients with low or absent renal function2007
Dr Jo Lee
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Sharon Erb
et al.		Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer2007
Professor Alan Boddy
Julieann Sludden
Melanie Griffin
Emeritus Professor Herbie Newell
Professor Stephen O'Brien
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia2007
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al.		A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules2005
12